AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Friends jogging

Resources & Tools

Exercise as part of your treatment plan

Register for this free, hour-long webinar

READ MORE

Special reports

Are we too focused on the search for a Parkinson’s cure?

We ask Parkinson’s experts for their views on this controversial debate

READ MORE
forked wooden pedestrian walkway

sponsored article

PD in Practice

Could your subconscious mind affect your Parkinson’s treatment outcomes?

Drivers for decisions – new insights may help optimise treatment

READ MORE